Opendata, web and dolomites

ImmuneHunter SIGNED

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Total Cost €


EC-Contrib. €






 ImmuneHunter project word cloud

Explore the words cloud of the ImmuneHunter project. It provides you a very rough idea of what is the project "ImmuneHunter" about.

status    restricted    therapeutics    accurately    figure    entry    format    signed    small    demand    ageing    sophisticated    tests    spending    discover    patient    diagnostic    grows    data    million    deaths    unable    times    half    accuracy    protobios    bioinformatics    competing    pilot    breaking    applies    illness    death    nearly    causes    analysed    diagnose    73    immune    multiplexed    resolution    health    throughput    full    platform    molecular    overview    mind    25    handle    annual    clinical    frequent    unprecedented    capacity    vaccines    radically    platforms    discovery    diagnostics    contribution    cancer    disease    heart    healthy    analyzing    limited    signatures    variation    companies    establishing    services    technologies    scalability    ict    biotech    antibody    2018    chronic    profiling    applicable    distinguish    routine    tool    least    healthcare    mimotope    market    ground    amounts    repertoire    premature    capability    empower    mva    reduce    simultaneously    2020    contracts    diseases    six    characterization    detect    biomarkers    advantage    analytical    additional    revenues    huge    service    superior    discovered    corresponding   

Project "ImmuneHunter" data sheet

The following table provides information about the project.


Organization address
address: MAEALUSE 4
postcode: 12618
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Estonia [EE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROTOBIOS OU EE (TALLINN) coordinator 50˙000.00


 Project objective

Chronic diseases (cancer, heart and mind diseases) are the leading causes of illness and death. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature). To radically reduce the related healthcare spending and contribute to healthy ageing, it is important to diagnose these diseases as early and accurately as possible by analyzing biomarkers. However, the current analytical platforms have been unable to handle the huge amounts of data that need to be analysed for the discovery of new biomarkers, and as a result: (1) only a small number of new biomarkers have been discovered and (2) current routine diagnostic tests are able to provide only a very restricted overview of patient’s health status.

Protobios applies a ground-breaking high-throughput antibody repertoire characterization technology Mimotope Variation Analysis (MVA) to discover new biomarkers, develop novel multiplexed diagnostics, and empower the discovery and development of therapeutics and vaccines. Compared to competing technologies, MVA is superior because (1) it allows to detect and distinguish many different disease signatures simultaneously and (2) the scalability and associated low cost of the MVA process make it applicable for frequent analysis, providing the additional advantage of establishing a robust health assessment tool.

We have used MVA technology to provide clinical diagnostics' development services in a pilot format to a limited number of biotech companies and research institutions. We have witnessed growing demand and signed six-figure contracts for 2018.

The key component of MVA is a sophisticated bioinformatics platform that enables molecular profiling of the immune response at an unprecedented resolution and accuracy. For full-scale market entry, we need to scale up the technical capability of the ICT platform so that the MVA service capacity grows by at least 100 times (corresponding to annual revenues of €20-25 million).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNEHUNTER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNEHUNTER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)


CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More